BIOGEN INC (BIIB) Stock Fundamental Analysis
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
164.68 USD
-2.87 (-1.71%)
162.7 USD
-1.98 (-1.2%)
Taking everything into account, BIIB scores 6 out of 10 in our fundamental rating. BIIB was compared to 533 industry peers in the Biotechnology industry. BIIB gets an excellent profitability rating and is at the same time showing great financial health properties. BIIB is cheap, but on the other hand it scores bad on growth. This makes BIIB very considerable for value investing!
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
BIIB had a positive operating cash flow in the past year.
BIIB had positive earnings in each of the past 5 years.
Each year in the past 5 years BIIB had a positive operating cash flow.
1.2 Ratios
The Return On Assets of BIIB (5.51%) is better than 92.12% of its industry peers.
BIIB has a better Return On Equity (8.84%) than 92.68% of its industry peers.
BIIB has a better Return On Invested Capital (9.70%) than 94.56% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIIB is significantly below the industry average of 15.88%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
BIIB has a better Profit Margin (15.99%) than 93.43% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 28.50%, BIIB belongs to the best of the industry, outperforming 96.44% of the companies in the same industry.
BIIB's Operating Margin has declined in the last couple of years.
The Gross Margin of BIIB (75.24%) is better than 83.68% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
The number of shares outstanding for BIIB has been reduced compared to 5 years ago.
The debt/assets ratio for BIIB has been reduced compared to a year ago.
2.2 Solvency
BIIB has an Altman-Z score of 3.21. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BIIB (3.21) is better than 72.05% of its industry peers.
BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as BIIB would need 2.78 years to pay back of all of its debts.
The Debt to FCF ratio of BIIB (2.78) is better than 93.06% of its industry peers.
BIIB has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
BIIB has a Debt to Equity ratio of 0.35. This is in the lower half of the industry: BIIB underperforms 70.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.21 |
ROIC/WACC1.17
WACC8.31%
2.3 Liquidity
A Current Ratio of 2.72 indicates that BIIB has no problem at all paying its short term obligations.
BIIB's Current ratio of 2.72 is on the low side compared to the rest of the industry. BIIB is outperformed by 66.79% of its industry peers.
A Quick Ratio of 2.04 indicates that BIIB has no problem at all paying its short term obligations.
BIIB has a Quick ratio of 2.04. This is in the lower half of the industry: BIIB underperforms 72.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
Looking at the last year, BIIB shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
The Earnings Per Share is expected to grow by 0.52% on average over the next years.
Based on estimates for the next years, BIIB will show a decrease in Revenue. The Revenue will decrease by -0.65% on average per year.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.84 indicates a reasonable valuation of BIIB.
BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.75% of the companies in the same industry.
BIIB is valuated cheaply when we compare the Price/Earnings ratio to 25.56, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 10.55 indicates a reasonable valuation of BIIB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.56% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.62, BIIB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.84 | ||
| Fwd PE | 10.55 |
4.2 Price Multiples
98.12% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
98.31% of the companies in the same industry are more expensive than BIIB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.67 | ||
| EV/EBITDA | 7.26 |
4.3 Compensation for Growth
BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
164.68
-2.87 (-1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change1.97%
Ins Owners0.14%
Ins Owner Change5.21%
Market Cap24.14B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target175.03 (6.28%)
Short Float %3.86%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)1.06%
PT rev (3m)1.25%
EPS NQ rev (1m)-54.08%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-4.15%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.3%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.84 | ||
| Fwd PE | 10.55 | ||
| P/S | 2.4 | ||
| P/FCF | 10.67 | ||
| P/OCF | 9.84 | ||
| P/B | 1.33 | ||
| P/tB | 10.12 | ||
| EV/EBITDA | 7.26 |
EPS(TTM)16.74
EY10.17%
EPS(NY)15.61
Fwd EY9.48%
FCF(TTM)15.44
FCFY9.37%
OCF(TTM)16.74
OCFY10.16%
SpS68.66
BVpS124.19
TBVpS16.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.16%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.56% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.21 |
F-Score5
WACC8.31%
ROIC/WACC1.17
Cap/Depr(3y)54.41%
Cap/Depr(5y)68.88%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.36%
Profit Quality(5y)121%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.54%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.48%
OCF growth 3Y-7.55%
OCF growth 5Y-16.48%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status for BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for BIIB stock?
The Earnings per Share (EPS) of BIOGEN INC (BIIB) is expected to decline by -5.79% in the next year.